Orion Pharma Selects ChemDiv, Inc. as a Partner in Drug Discovery Services
SAN DIEGO, Nov. 30 /PRNewswire/ -- ChemDiv, Inc. and Orion Pharma today announced that Orion has chosen ChemDiv as a discovery partner in small molecule therapeutics for Orion's priority targets.
Under the terms of the agreement, ChemDiv will deploy the Discovery outSource(TM) platform for Orion's discovery program, including the world's largest commercially available chemical library, proprietary rational design, assay development, and bioscreening. ChemDiv will screen rationally designed chemical libraries against Orion's proprietary targets, and Orion will select hit series for subsequent lead optimization. Financial terms and identity of drug targets were not disclosed. The agreement provides options for expanding the discovery partnership.
"I am very satisfied with the commitment and exchange of information in our joint effort. We have a good basis for success," said Dr. Ari Koivisto, Orion's contact person in the collaboration. "Our partnership with ChemDiv complements our in-house discovery effort in this particular project," stated Dr. Antti Haapalinna, Director of Nonclinical R&D, Orion Pharma, Orion Corporation.
"We are delighted to offer discovery services to Orion Pharma in this partnership. We are especially pleased with the constructive dialog with Orion R&D, based on our mutual understanding and shared goals. Based on ChemDiv's diligence and track record, we are confident of success and look forward to expansion of this collaboration in the near future," commented Nikolay Savchuk, President and CEO of ChemDiv, Inc.
About Orion Corporation
Orion Corporation (OMX: ORNAV, ORNBV) is one of the leading pharmaceutical companies in the northern Europe. Orion develops, manufactures and markets pharmaceuticals, active pharmaceutical ingredients and diagnostic tests for global markets. Pharmaceuticals generate about 95% of the Group's net sales, of which proprietary patented pharmaceutical innovations contribute a considerable part. The core therapy areas in Orion's product and research strategy are central nervous system disorders, cardiology and critical care, urology and oncology. Stalevo(R) and Comtess(R) / Comtan(R), treatments originated by Orion for Parkinson 's disease, are the largest products by sales in Orion's portfolio. For additional information, please visit http://www.orion.fi.
About ChemDiv, Inc.
ChemDiv (http://www.chemdiv.com) is a global chemistry-driven contract research organization focused on identifying and delivering pre-clinical opportunities and advanced R&D services for the development of treatments for life-threatening diseases. For over 17 years, ChemDiv has provided its Discovery outSource(TM) solutions to life science partners, including medicinal and synthetic chemistry, pre-clinical development, screening libraries, and global logistics. ChemDiv's international research team encompasses 550 chemists and biologists in San Diego and Moscow based R&D centers.
CONTACT: Ron Demuth, General Manager of ChemDiv, Inc., +1-858-794-4860,
Fax, +1-858-794-4931, rdemuth@chemdiv.com
Web site: http://www.chemdiv.com/
http://www.orion.fi/